Germany · Delayed Price · Currency is EUR OncoZenge AB Statistics
Total Valuation
OncoZenge AB has a market cap or net worth of EUR 6.41 million. The enterprise value is 6.03 million.
| Market Cap | 6.41M |
| Enterprise Value | 6.03M |
Important Dates
The next estimated earnings date is Wednesday, February 18, 2026.
| Earnings Date | Feb 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 12.65M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.57% |
| Shares Change (QoQ) | +5.97% |
| Owned by Insiders (%) | 33.69% |
| Owned by Institutions (%) | 11.21% |
| Float | 5.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.45 |
| PB Ratio | 7.61 |
| P/TBV Ratio | 28.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.80 |
| EV / Sales | 23.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.28, with a Debt / Equity ratio of 0.81.
| Current Ratio | 4.28 |
| Quick Ratio | 4.13 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -569.30 |
Financial Efficiency
Return on equity (ROE) is -78.64% and return on invested capital (ROIC) is -36.49%.
| Return on Equity (ROE) | -78.64% |
| Return on Assets (ROA) | -31.88% |
| Return on Invested Capital (ROIC) | -36.49% |
| Return on Capital Employed (ROCE) | -50.83% |
| Revenue Per Employee | 251,725 |
| Profits Per Employee | -773,807 |
| Employee Count | 1 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.83% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +35.83% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 49.52 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OncoZenge AB had revenue of EUR 251,725 and -773,807 in losses. Loss per share was -0.07.
| Revenue | 251,725 |
| Gross Profit | 251,725 |
| Operating Income | -772,540 |
| Pretax Income | -773,807 |
| Net Income | -773,807 |
| EBITDA | n/a |
| EBIT | -772,540 |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 1.05 million in cash and 678,381 in debt, giving a net cash position of 369,944.
| Cash & Cash Equivalents | 1.05M |
| Total Debt | 678,381 |
| Net Cash | 369,944 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 841,554 |
| Book Value Per Share | 0.07 |
| Working Capital | 900,347 |
Cash Flow
| Operating Cash Flow | -703,979 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -306.90% |
| Pretax Margin | -307.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoZenge AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.57% |
| Shareholder Yield | -1.57% |
| Earnings Yield | -12.08% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OncoZenge AB has an Altman Z-Score of -2.35 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.35 |
| Piotroski F-Score | 1 |